Journal article
Safety and Effectiveness of a Next-Generation Contact Force Catheter: Results of the TactiSense Trial
MY Lo, P Sanders, P Sommer, JM Kalman, UR Siddiqui, S Sundaram, C Piorkowski, N Olson, SM Madej, DN Gibson
Jacc Clinical Electrophysiology | ELSEVIER | Published : 2021
Abstract
Objectives: The objective of this clinical trial was to evaluate the safety and effectiveness of the TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) (Abbott, Abbott Park, Illinois) for the treatment of drug-refractory, symptomatic paroxysmal atrial fibrillation (PAF). Background: Catheter ablation of atrial fibrillation (AF) is an established therapy for the treatment of PAF. Ablation technology is evolving with the primary goals of improving efficacy and safety of the procedure. Methods: This was a multicenter single-arm trial evaluating a novel ablation catheter for the treatment of PAF. A total of 156 subjects were enrolled at 19 sites in the United States, Europe..
View full abstractGrants
Funding Acknowledgements
This study was funded by Abbott Dr. Lo is a consultant and has received honorarium from Abbott. Prof. Sanders is on advisory boards for Medtronic, Abbott, Boston Scientific, Pacemate, and CathRx; and has received speaking honoraria and consulting fees from Medtronic, Abbott, and Boston Scientific. Prof. Sommer is on advisory boards for Medtronic, Abbott, Biosense Webster, Boston Scientific, and Medtronic. Prof. Kalman has research and fellowship support from Abbott, Biosense Webster, and Medtronic. Dr. Siddiqui has consultation and speaking honoraria from Abbott. Dr. Sundaram has speaking honoraria from Abbott and Medtronic. Dr. Piorkowski is employed in industry as Chief Medical Officer for Electrophysiology at Abbott. Dr. Olson has consultation and speaking honoraria from Abbott, Medtronic, and Biosense Webster. Mr. Madej is employed in industry as Associate Director, Clinical Research at Abbott. Dr. Gibson is a consultant for Abbott, Biosense Webster, and Boston Scientific.